{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:46:05Z","timestamp":1777380365782,"version":"3.51.4"},"reference-count":108,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["101168626"],"award-info":[{"award-number":["101168626"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["101072828"],"award-info":[{"award-number":["101072828"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["01EK2105B"],"award-info":[{"award-number":["01EK2105B"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["01KU2307"],"award-info":[{"award-number":["01KU2307"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"German Federal Ministry of Education and Research(BMBF) via UPTAKE","doi-asserted-by":"publisher","award":["101168626"],"award-info":[{"award-number":["101168626"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"German Federal Ministry of Education and Research(BMBF) via UPTAKE","doi-asserted-by":"publisher","award":["101072828"],"award-info":[{"award-number":["101072828"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"German Federal Ministry of Education and Research(BMBF) via UPTAKE","doi-asserted-by":"publisher","award":["01EK2105B"],"award-info":[{"award-number":["01EK2105B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"German Federal Ministry of Education and Research(BMBF) via UPTAKE","doi-asserted-by":"publisher","award":["01KU2307"],"award-info":[{"award-number":["01KU2307"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ERA PerMed SIGNAL project","award":["101168626"],"award-info":[{"award-number":["101168626"]}]},{"name":"ERA PerMed SIGNAL project","award":["101072828"],"award-info":[{"award-number":["101072828"]}]},{"name":"ERA PerMed SIGNAL project","award":["01EK2105B"],"award-info":[{"award-number":["01EK2105B"]}]},{"name":"ERA PerMed SIGNAL project","award":["01KU2307"],"award-info":[{"award-number":["01KU2307"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Chronic kidney disease (CKD) is a global health burden that affects close to one billion individuals. As many healthcare systems struggle to accommodate existing patients, CKD incidence and related costs are projected to continue rising. Based on a systematic search, this narrative review offers an in-depth assessment of advances in CKD pharmacotherapy published between 2020 and 2025, with a specific emphasis on drug combinations. Various treatment approaches for CKD exist, many of them targeting different mechanisms. Therefore, combining multiple medications could provide patients with better outcomes, though this comes with the risk of increased adverse effects and unnecessary costs. Alternatively, using biomarkers presents an opportunity to ascertain the most appropriate treatments specifically tailored to an individual\u2019s molecular profile, thus personalizing CKD management. The second part of this review presents the current state-of-the-art methods to guide CKD therapy based on markers predicting treatment response. Collectively, this review presents possible pathways toward more effective CKD treatment.<\/jats:p>","DOI":"10.3390\/biom15060809","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T08:51:04Z","timestamp":1749027064000},"page":"809","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?"],"prefix":"10.3390","volume":"15","author":[{"given":"Sajjad","family":"Biglari","sequence":"first","affiliation":[{"name":"Mosaiques Diagnostics GmbH, 30659 Hannover, Germany"},{"name":"Department of Nephrology, Transplantation Medicine and Internal Diseases Institute of Internal Diseases, Wroclaw Medical University, 50-551 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0323-0306","authenticated-orcid":false,"given":"Harald","family":"Mischak","sequence":"additional","affiliation":[{"name":"Mosaiques Diagnostics GmbH, 30659 Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Beige","sequence":"additional","affiliation":[{"name":"Kuratorium for Dialysis and Transplantation (KfH) Leipzig, 04129 Leipzig, Germany"},{"name":"Department of Nephrology, St. Georg Hospital Leipzig, 04129 Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Latosinska","sequence":"additional","affiliation":[{"name":"Mosaiques Diagnostics GmbH, 30659 Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-2534","authenticated-orcid":false,"given":"Justyna","family":"Siwy","sequence":"additional","affiliation":[{"name":"Mosaiques Diagnostics GmbH, 30659 Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0588-1551","authenticated-orcid":false,"given":"Miros\u0142aw","family":"Banasik","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantation Medicine and Internal Diseases Institute of Internal Diseases, Wroclaw Medical University, 50-551 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of Chronic Kidney Disease: An Update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of Death in Patients with Reduced Kidney Function","volume":"26","author":"Thompson","year":"2015","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"gfaf057","DOI":"10.1093\/ndt\/gfaf057","article-title":"ABCDE to Identify and Prevent Chronic Kidney Disease: A Call to Action","volume":"1\u201313","author":"Ferro","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Stolpe, S., Kowall, B., Scholz, C., Stang, A., and Blume, C. (2021). High Unawareness of Chronic Kidney Disease in Germany. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph182211752"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic Kidney Disease and the Global Public Health Agenda: An International Consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic Kidney Disease Diagnosis and Management: A Review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1007\/s12325-023-02608-9","article-title":"Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme","volume":"40","author":"Jha","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/ndt\/gfae212","article-title":"Combination Therapy: An Upcoming Paradigm to Improve Kidney and Cardiovascular Outcomes in Chronic Kidney Disease","volume":"40","author":"Alicic","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4239\/wjd.v3.i1.1","article-title":"Renal Hyperfiltration Related to Diabetes Mellitus and Obesity in Human Disease","volume":"3","author":"Sasson","year":"2012","journal-title":"World J. Diabetes"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Patera, F., Gatticchi, L., Cellini, B., Chiasserini, D., and Reboldi, G. (2024). Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities. Biomolecules, 14.","DOI":"10.3390\/biom14010137"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gu, Y.-Y., Liu, X.-S., Huang, X.-R., Yu, X.-Q., and Lan, H.-Y. (2020). Diverse Role of TGF-\u03b2 in Kidney Disease. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00123"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Plonsky-Toder, M., Magen, D., and Pollack, S. (2023). Innate Immunity and CKD: Is There a Significant Association?. Cells, 12.","DOI":"10.3390\/cells12232714"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e202400279","DOI":"10.1002\/pmic.202400279","article-title":"Investigation of the Urinary Peptidome to Unravel Collagen Degradation in Health and Kidney Disease","volume":"1\u201313","author":"Mina","year":"2024","journal-title":"Proteomics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","article-title":"Kidney Fibrosis: From Mechanisms to Therapeutic Medicines","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A Web and Mobile App for Systematic Reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"ONTARGET Investigators, Yusuf, S., Teo, K.K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P., and Anderson, C. (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N. Engl. J. Med., 358, 1547\u20131559.","DOI":"10.1056\/NEJMoa0801317"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients with Diabetic Nephropathy: A Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone Reduces Risk of Incident Heart Failure in Patients with Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","article-title":"Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis","volume":"18","author":"Sarafidis","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A Prespecified Exploratory Analysis from FIDELITY Examined Finerenone Use and Kidney Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in Predominantly Advanced CKD and Type 2 Diabetes with or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy","volume":"7","author":"Rossing","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/HYPERTENSIONAHA.122.19744","article-title":"Blood Pressure and Cardiorenal Outcomes with Finerenone in Chronic Kidney Disease in Type 2 Diabetes","volume":"79","author":"Ruilope","year":"2022","journal-title":"Hypertension"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: FINE-HEART Pooled Analysis of Cardiovascular, Kidney and Mortality Outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A Comparative Post Hoc Analysis of Finerenone and Spironolactone in Resistant Hypertension in Moderate-to-Advanced Chronic Kidney Disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer vs. Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease (AMBER): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet Lond. Engl."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zhang, M.-Z., Bao, W., Zheng, Q.-Y., Wang, Y.-H., and Sun, L.-Y. (2022). Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.819327"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s40620-024-02070-y","article-title":"First Interim Results from FINE-REAL: A Prospective, Non-Interventional, Phase 4 Study Providing Insights into the Use and Safety of Finerenone in a Routine Clinical Setting","volume":"37","author":"Nicholas","year":"2024","journal-title":"J. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.33696\/Pharmacol.6.048","article-title":"Aldosterone Synthase Inhibitors for Treatment of Hypertension and Chronic Kidney Disease","volume":"6","author":"Mikhail","year":"2024","journal-title":"Arch. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and Safety of Aldosterone Synthase Inhibition with and without Empagliflozin for Chronic Kidney Disease: A Randomised, Controlled, Phase 2 Trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"ref_40","first-page":"1175","article-title":"The Potential for Improving Cardio-Renal Outcomes in Chronic Kidney Disease with the Aldosterone Synthase Inhibitor Vicadrostat (BI 690517): A Rationale for the EASi-KIDNEY Trial","volume":"40","author":"Judge","year":"2024","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","article-title":"Effect of Dapagliflozin on the Rate of Decline in Kidney Function in Patients with Chronic Kidney Disease with and without Type 2 Diabetes: A Prespecified Analysis from the DAPA-CKD Trial","volume":"9","author":"Heerspink","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A Pre-Specified Analysis of the DAPA-CKD Trial Demonstrates the Effects of Dapagliflozin on Major Adverse Kidney Events in Patients with IgA Nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/ndt\/gfab335","article-title":"Safety and Efficacy of Dapagliflozin in Patients with Focal Segmental Glomerulosclerosis: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) Trial","volume":"37","author":"Wheeler","year":"2022","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of Dapagliflozin on Urinary Albumin Excretion in Patients with Chronic Kidney Disease with and without Type 2 Diabetes: A Prespecified Analysis from the DAPA-CKD Trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S2213-8587(21)00295-3","article-title":"Dapagliflozin and New-Onset Type 2 Diabetes in Patients with Chronic Kidney Disease or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials","volume":"10","author":"Rossing","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"The","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of Ertugliflozin on Kidney Composite Outcomes, Renal Function and Albuminuria in Patients with Type 2 Diabetes Mellitus: An Analysis from the Randomised VERTIS CV Trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/dom.15019","article-title":"Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes and Stage 3 Chronic Kidney Disease","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.2337\/dc21-1081","article-title":"Kidney Outcomes Associated with SGLT2 Inhibitors vs. Other Glucose-Lowering Drugs in Real-World Clinical Practice: The Japan Chronic Kidney Disease Database","volume":"44","author":"Nagasu","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e019463","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of Sodium\/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials","volume":"10","author":"Teo","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Puglisi, S., Rossini, A., Poli, R., Dughera, F., Pia, A., Terzolo, M., and Reimondo, G. (2021). Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.738848"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE Trial Indicate an Acute Drop in Estimated Glomerular Filtration Rate during Treatment with Canagliflozin with Implications for Clinical Practice","volume":"99","author":"Oshima","year":"2021","journal-title":"Kidney Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1681\/ASN.2022030306","article-title":"Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD","volume":"33","author":"Jongs","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4093\/dmj.2023.0201","article-title":"Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis","volume":"48","author":"Chuang","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/ndt\/gfac280","article-title":"Extrapolated Longer-Term Effects of the DAPA-CKD Trial: A Modelling Analysis","volume":"38","author":"McEwan","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential Kidney Protection with Liraglutide and Semaglutide: Exploratory Mediation Analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of Semaglutide with and without Concomitant SGLT2 Inhibitor Use in Participants with Type 2 Diabetes and Chronic Kidney Disease in the FLOW Trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive Summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: An Update Based on Rapidly Emerging New Evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bcp.12064","article-title":"Endothelin Antagonists for Diabetic and Non-Diabetic Chronic Kidney Disease","volume":"76","author":"Kohan","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease (SONAR): A Double-Blind, Randomised, Placebo-Controlled Trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet Lond. Engl."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in Patients with IgA Nephropathy: A Prespecified Interim Analysis from a Randomised, Double-Blind, Active-Controlled Clinical Trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","article-title":"Sparsentan: First Approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN Effect of FInerenone anD EmpaglifloziN in Participants with Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc22-0294","article-title":"Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis","volume":"45","author":"Rossing","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared with Conventional Care in Patients with Type 2 Diabetes and Albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients with CKD Treated with Mineralocorticoid Receptor Antagonists","volume":"7","author":"Provenzano","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and Safety of Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes by GLP-1RA Treatment: A Subgroup Analysis from the FIDELIO-DKD Trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.kint.2020.09.026","article-title":"New Insights from SONAR Indicate Adding Sodium Glucose Co-Transporter 2 Inhibitors to an Endothelin Receptor Antagonist Mitigates Fluid Retention and Enhances Albuminuria Reduction","volume":"99","author":"Heerspink","year":"2021","journal-title":"Kidney Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease (ZENITH-CKD): A Multicentre, Randomised, Active-Controlled, Phase 2b, Clinical Trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ahj.2018.07.012","article-title":"The International Polycap Study-3 (TIPS-3): Design, Baseline Characteristics and Challenges in Conduct","volume":"206","author":"Joseph","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","article-title":"Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases (PolyIran): A Pragmatic, Cluster-Randomised Trial","volume":"394","author":"Roshandel","year":"2019","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill Strategy in Secondary Cardiovascular Prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-019-0241-1","article-title":"Biomarker-Guided Therapy for Colorectal Cancer: Strength in Complexity","volume":"17","author":"Sveen","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_85","first-page":"296","article-title":"Predicting Albuminuria Response to Spironolactone Treatment with Urinary Proteomics in Patients with Type 2 Diabetes and Hypertension","volume":"33","author":"Lindhardt","year":"2018","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ndt\/gfad223","article-title":"Urinary Peptide Analysis to Predict the Response to Blood Pressure Medication","volume":"39","author":"Mavrogeorgis","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_87","first-page":"2826","article-title":"Dynamics of Urine Proteomics Biomarker and Disease Progression in Patients with IgA Nephropathy","volume":"38","author":"Peters","year":"2023","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Jaimes Campos, M.A., And\u00fajar, I., Keller, F., Mayer, G., Rossing, P., Staessen, J.A., Delles, C., Beige, J., Glorieux, G., and Clark, A.L. (2023). Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study. Pharmaceuticals, 16.","DOI":"10.1101\/2023.08.01.23293501"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00125-021-05512-5","article-title":"Effects of the SGLT2 Inhibitor Canagliflozin on Plasma Biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS Trial","volume":"64","author":"Sen","year":"2021","journal-title":"Diabetologia"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Shiratori-Aso, S., Nakazawa, D., Nishio, S., Ueda, Y., Eguchi, M., Yokoyama, A., Yoshikawa, J., Kudo, T., Watanabe-Kusunoki, K., and Takeda-Otera, S. (2022). Soluble Interleukin-2 Receptor Predicts Treatment Outcome in Patients with Autoimmune Tubulointerstitial Nephritis. A Preliminary Study. Front. Med., 9.","DOI":"10.3389\/fmed.2022.827388"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.37796\/2211-8039.1205","article-title":"The Level of Transforming Growth Factor Beta as a Possible Predictor of Cyclophosphamide Response in Children with Steroid-Resistant Nephrotic Syndrome","volume":"11","author":"Widiasta","year":"2021","journal-title":"BioMedicine"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Teisseyre, M., Cremoni, M., Boyer-Suavet, S., Crepin, T., Benzaken, S., Zorzi, K., Esnault, V., Brglez, V., and Seitz-Polski, B. (2021). Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.738788"},{"key":"ref_93","first-page":"16302","article-title":"Assessment of Laboratory Predictors of Steroid Response in Nephrotic Syndrome","volume":"10","author":"Jamee","year":"2022","journal-title":"Int. J. Pediatr."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa2202396","article-title":"Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants","volume":"388","author":"Egbuna","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Kapsia, E., Marinaki, S., Michelakis, I., Liapis, G., Sfikakis, P.P., Boletis, J., and Tektonidou, M.G. (2022). Predictors of Early Response, Flares, and Long-Term Adverse Renal Outcomes in Proliferative Lupus Nephritis: A 100-Month Median Follow-Up of an Inception Cohort. J. Clin. Med., 11.","DOI":"10.3390\/jcm11175017"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Capelli, I., Ribichini, D., Provenzano, M., Vetrano, D., Aiello, V., Cianciolo, G., Vicennati, V., Tomassetti, A., Moschione, G., and Berti, S. (2023). Impact of Baseline Clinical Variables on SGLT2i\u2019s Antiproteinuric Effect in Diabetic Kidney Disease. Life, 13.","DOI":"10.3390\/life13041061"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1681\/ASN.2021030391","article-title":"Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial","volume":"32","author":"Heerspink","year":"2021","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12933-018-0697-9","article-title":"Urinary Proteomics for Prediction of Mortality in Patients with Type 2 Diabetes and Microalbuminuria","volume":"17","author":"Currie","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ekir.2017.06.004","article-title":"Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker","volume":"2","author":"Pontillo","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e010310","DOI":"10.1136\/bmjopen-2015-010310","article-title":"Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy in TYpe 2 Diabetic Patients with Normoalbuminuria (PRIORITY): Essential Study Design and Rationale of a Randomised Clinical Multicentre Trial","volume":"6","author":"Lindhardt","year":"2016","journal-title":"BMJ Open"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Argil\u00e9s, \u00c0., Siwy, J., Duranton, F., Gayrard, N., Dakna, M., Lundin, U., Osaba, L., Delles, C., Mourad, G., and Weinberger, K.M. (2013). CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062837"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","article-title":"Early Detection of Diabetic Kidney Disease by Urinary Proteomics and Subsequent Intervention with Spironolactone to Delay Progression (PRIORITY): A Prospective Observational Study and Embedded Randomised Placebo-Controlled Trial","volume":"8","author":"Tofte","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Ortiz, M.E., Pontillo, C., Rodr\u00edguez, M., Z\u00fcrbig, P., Mischak, H., and Ortiz, A. (2018). Novel Urinary Biomarkers for Improved Prediction of Progressive eGFR Loss in Early Chronic Kidney Disease Stages and in High Risk Individuals Without Chronic Kidney Disease. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-34386-8"},{"key":"ref_104","first-page":"441","article-title":"Cost-Effectiveness of Screening Type 2 Diabetes Patients for Chronic Kidney Disease Progression with the CKD273 Urinary Peptide Classifier as Compared to Urinary Albumin Excretion","volume":"33","author":"Critselis","year":"2018","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Latosinska, A., Mina, I.K., Nguyen, T.M.N., Golovko, I., Keller, F., Mayer, G., Rossing, P., Staessen, J.A., Delles, C., and Beige, J. (2025). In Silico Prediction of Optimal Multifactorial Intervention in CKD. medRxiv.","DOI":"10.1101\/2025.02.14.25322292"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"sfad137","DOI":"10.1093\/ckj\/sfad137","article-title":"Cost-Effectiveness of Screening for Chronic Kidney Disease in the General Adult Population: A Systematic Review","volume":"17","author":"Yeo","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.21037\/atm-2020-117","article-title":"Paving the Way to Precision Medicine for Diabetic Kidney Disease: The PRIORITY Trial","volume":"8","author":"Schechter","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Shukri, A., Mettang, T., Scheckel, B., Schellartz, I., Simic, D., Scholten, N., M\u00fcller, M., and Stock, S. (2022). Hemodialysis and Peritoneal Dialysis in Germany from a Health Economic View-A Propensity Score Matched Analysis. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph192114007"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/6\/809\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:54Z","timestamp":1760032014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/6\/809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":108,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["biom15060809"],"URL":"https:\/\/doi.org\/10.3390\/biom15060809","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]}}}